CD44 and colorectal carcinoma: In this study, although the DNA methylation levels of CD44 gene are not significantly varied between the tumoral and non-tumoral tissues of CRC, the potential of CD44v6 as a biomarker in CRC progression should be further verified through applying a specific immunohistochemical antibody against CD44v6.